Curenetics
Adwait Joshi is an accomplished student currently pursuing a Bachelor of Medicine, Bachelor of Surgery (MBBS/BSc) and a BSc in Surgical Design Technology and Innovation at Imperial College London. With a diverse range of leadership and research experiences, Adwait serves as Club Captain, Treasurer, and 2nd XI Captain at Imperial Medicals Cricket Club, and has taken on roles as an Undergraduate Researcher focusing on CT radiomics and as an Intern at Curenetics. Adwait has also contributed as a Freelance Market Research Analyst and is set to undertake a BSc Research Project at Tokyo Medical and Dental University, presenting findings on biomarkers for lymph node metastasis in gastric cancer at the ESSO 2024 conference. Additional leadership roles include presidency of the Imperial College Oncology Society and a position as a GP Notes Summarizer at NHS. Adwait's strong academic background is complemented by a history of involvement in various educational societies and initiatives.
This person is not in any teams
This person is not in any offices
Curenetics
1 followers
Curenetics is a fast-evolving and advancing start-up, working hard to defeat cancer using medical technology. Cancer treatment varies from patient to patient and many cancer types now require immune-oncologic treatment or other forms of targeted therapy. How a patient responds to their treatment regime is not fully known which can result in patients suffering from unwanted side effects or developing potentially life-threatening immune-mediated toxicities. We are currently working towards developing cancer treatment response models using artificial intelligence. We aim to predict response to immuno-oncologic treatments in cancer patients by leveraging our platform’s capability to find features within a large array of asynchronous clinical and genomic data. We are identifying biomarkers that will predict response to immunotherapy, even before starting treatment. At the same time, Curenetics is also building a flagship AI model to match cancer patients to the right clinical trial, whatever stage of treatment you are in. Through our machine learning-driven algorithms, domain expertise, and ability to combine cancer molecular profiling data, we are giving patients hope by helping to recruit them to the most suitable clinical trials available. At the same time, supporting trial sponsors to meet their recruitment targets, saving costs, and reducing time to trial completion.